found that steps a and b are also required for obtaining lopinavir cyclohexane solvate in accordance with another aspect of the present invention there is provided a novel desolvated crystalline form of lopinavir designated as form h1 characterized by peaks in the powder x ray diffraction spectrum having 2 u03b8 angle positions at about 5 6 8 6 13 8 14 3 19 2 and 19 5 u00b1 0 2 degrees the powdered x ray diffractogram pxrd of lopinavir desolvated crystalline form h1 is shown in fig2 lopinavir desolvated crystalline form h1 of present invention is further characterized by a differential scanning calorimetry dsc thermogram as shown in fig3 the dsc thermogram of the lopinavir desolvated crystalline form h1 exhibits a melting small endotherm at about 111 deg c followed by a sharp endotherm at about 115 deg c when differential scanning calorimetry is performed with a scanning rate of 1 deg c per minute from 50 deg c to 150 deg c it has surprisingly been found that a novel lopinavir desolvated crystalline form h1 can be obtained simply by heating the novel lopinavir cyclohexane solvate thus the novel lopinavir cyclohexane solvate constitutes useful intermediate for preparing the novel lopinavir desolvated crystalline form h1 in accordance with another aspect of the present invention there is provided a process for the preparation of lopinavir desolvated crystalline form h1 which comprises heating lopinavir cyclohexane solvate at above 80 deg c preferably heating may be performed at 80 deg c to 120 deg c the heating may be carried out until lopinavir cyclohexane solvate is completely converted into lopinavir desolvated crystalline form h1 in accordance.